'For
the quarter ending Sept 2023, consolidated Net sales (including other operating income) of Ajanta Pharma has increased 9.63% to Rs 1028.44 crore compared to quarter ended Sept 2022. Operating profit margin has jumped from 20.93% to 28.26%, leading to 48.04% rise in operating profit to Rs 290.66 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 22.22% to 21.44%. Purchase of finished goods cost rose from 4.42% to 4.51%. Employee cost increased from 20.13% to 21.31%. Other expenses fell from 32.00% to 24.87%. Other income fell 47.14% to Rs 21.33 crore. PBIDT rose 31.81% to Rs 311.99 crore. Provision for interest rose 136.36% to Rs 2.34 crore.
PBDT rose 31.37% to Rs 309.65 crore. Provision for depreciation rose 3.09% to Rs 33.71 crore.
Profit before tax grew 35.93% to Rs 275.94 crore. ...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Aug-2024)
AIA Engineering
Net down 5% on lower sales
-
(17-Aug-2024)
Voltas
Net jump 159% on good operating show
-
(17-Aug-2024)
ABB India
Net up 50% on good operating show
-
(17-Aug-2024)
NHPC
Sales down 2%, net down 1%
|
|